Combined adjuvant therapy of radically operated colorectal cancer patients

Robinson, Eliezer; Bartal, Arie H.; Cohen, Yoram; Haim, Nissim; Mohilever, Judith; Mekori, T.

doi:10.1007/bf00292869

Cited by 12 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy is recommended as adjuvant/neoadjuvant treatment for the majority of rectal cancer patients, 7 and radiotherapy combined with chemotherapy significantly reduces the risk of recurrence and metastasis. 8 Adjuvant chemotherapy contained 5-fluorouracil (5-Fu) is currently recommended for patients with stage III CRC after surgery. 9 – 11 Moreover, a combination of 5-Fu, irinotecan/oxaliplatin, and monoclonal antibodies significantly improved overall response rate (ORR), and prolonged survival time of advanced CRC patients.…”

Section: Introductionmentioning

confidence: 99%

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

Zhu

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: Although the survival rate of colorectal cancer (CRC) patients can be improved by surgery, radiotherapy, and chemotherapy, the resistance to 5-fluorouracil (5-Fu) affects the effect of chemotherapy and the prognosis of patients. An increasing number of studies showed that 5-Fu resistance was the main reason for the failure of colorectal cancer treatment. The poor prognosis of colorectal cancer greatly harms people's health. This study aimed to clarify the correlation between cyclin-dependent kinase 1 (CDK1) and 5-Fu-induced tumor resistance. Materials and Methods: Cell proliferation and invasion experiments showed that downregulation of CDK1 inhibited fluorouracil-resistant CRC cell proliferation. The expression level of CDK1 was detected in 5-Fu-resistant CRC cells in vitro. Tumor growth was inhibited by down-regulation of CDK1 in tumor xenograft mouse models. Results: We found that CDK1 was highly expressed in tumor tissues, especially in fluorouracil-resistant tissues. We also confirmed that the differential expression of 5-Fu in tumor tissues was related to tumor site, lymph node metastasis and stage. CDK1 promoted migration, invasion and inhibited apoptosis in 5-Fu-resistant CRC cells. Down-regulation of CDK1 inhibited fluorouracil-resistant CRC cell proliferation and tumorigenesis in vivo. Conclusion: High expression of CDK1 may lead to poor clinical prognosis, and inhibition of CDK1 enhances 5-Fu sensitivity in CRC. Our research suggested that CDK1 may be used to predict 5-Fu efficacy and as a therapeutic target for CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

Zhu

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A veterans administration surgical oncology group report

Higgins

Donaldson

Rogers³

et al. 1984

Cancer

View full text Add to dashboard Cite

Two hundred four patients with a microscopically incomplete resection for carcinoma of the colon or rectum were accepted for study. All patients were treated with 5‐flurouracil and methyl‐CCNU beginning about the second postoperative week. Concurrent immunotherapy with the methanol extraction residue of bacillus Calmette‐Guérin (MER) was randomly assigned to 103 patients. Treatment was continued as long as acceptable to the patient, and until clinical recurrence. Toxic reactions to the drug were not increased by the addition of MER, and seldom were servere enough to require the discrimination of therapy. No evidence of improved survival was seen in treated patients. On the contrary, survival in patients who experienced severe reactions to treatment may have been impaired by MER, with the period of impairment continuing after all adjuvant therapy was stopped. Similar proportions of treated and control deaths were attributable to residual or recurrent disease.

show abstract

Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure

Wunderlich¹,

Schiessel²,

Rainer³

et al. 1985

Journal of British Surgery

View full text Add to dashboard Cite

After radical surgery for colorectal cancer, 178 patients with a Dukes' B or C tumour were randomly assigned to one of three groups: A, controls (n = 62); B, chemotherapy (n = 59); C, immunotherapy (n = 57). Randomization criteria (age, sex, Dukes' stage, localization of tumour, operative procedure) were evenly distributed throughout the groups. After a median observation time of 30 months, statistical analyses were performed: survival and probability to be free of recurrence was described by Kaplan-Meier estimates of the survival function; for comparison of these survival functions, Breslow's test was used. Overall analyses show no benefit in the treatment group compared to controls. Separate analyses by Dukes' stages showed that in patients with Dukes' C tumours the probability of survival 40 months after surgery was 72 per cent in group C, 51 per cent in group B, and 33 per cent in group A. The differences between groups C and A, and B and A were statistically significant (P less than 0.02 and P less than 0.03 respectively). For a Dukes' C tumour the probability to be free of distant metastases at 30 months after surgery was 80 per cent in group B, 68 per cent in group C and 52 per cent in group A. Also for a Dukes' C tumour the probability to be free of liver metastases at 21 months after surgery was 83 per cent in group B, 81 per cent in group C, and 54 per cent in group A (significant differences: B-A and C-A P less than 0.04 for both). There was no influence on the estimated incidence of local recurrences for stage Dukes' C. Patients with a Dukes' B tumour did not benefit from either of the adjuvant therapy schemes.

show abstract

Combined adjuvant therapy of radically operated colorectal cancer patients

Cited by 12 publications

References 17 publications

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A veterans administration surgical oncology group report

Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure

Contact Info

Product

Resources

About